RING Finger Protein AO7 Supports NF-κB-mediated Transcription by Interacting with the Transactivation Domain of the p65 Subunit*

In this study, a novel interactor of the p65 subunit (RelA) of NF-κB has been explored by performing yeast two-hybrid screening using the transactivation domain (TAD) of p65 located in the C terminus as bait. We have isolated a RING finger motif-containing protein, AO7, previously identified as an interacting protein with a ubiquitin-conjugating enzyme, Ubc5B. We confirmed the protein-protein interaction between p65 and AO7 in vitro and in vivo and found that the C-terminal region of AO7 is responsible for the interaction with p65 TAD. AO7 was predominantly localized in the nucleus and activated the NF-κB-dependent gene expression upon stimulation with IL-1β or TNF or overexpression of NF-κB-inducing kinase. We found that both the RING finger and the C-terminal regions of AO7 were necessary for the transcriptional activation. When co-transfected with plasmids expressing Gal4-p65 fusion proteins containing various functional domains of p65, we found that p65 TAD was essential for the transcriptional activation mediated by AO7. Furthermore, the p65-mediated transcription was suppressed by a ubiquitination-defective AO7 mutant in which the essential Cys residue within the RING finger motif was substituted by Ser. These data suggest that AO7 interacts with the p65 TAD and modulates its transcriptional activity.

NF-κB plays a crucial role in many cellular events such as inflammation, host defense, cell survival, and proliferation (1–4). The members of the NF-κB family in mammalian cells include the proto-oncogene c-Rel, RelA (p65), RelB, NFκB1 (p50/105), and NFκB2 (p52/p100). Rel family members form hetero- and homodimers with distinct specificities in various combinations and the combination of p65 and p50 represents a major form of NF-κB (1–4). NF-κB exists in the cytoplasm in an inactive form associated with IκB inhibitor proteins (1, 2) and stimulation of cells with inducers such as phorbol esters, interleukin-1β (IL-1β), tumor necrosis factor (TNF) leads to the activation of extracellular signal-regulated kinase 1/3, NF-κB-inducing kinase (NIK), and IκB kinase (IKK) complex containing IκKα and IκKβ. Once phosphorylated by IKK complex, IκBs are ubiquitinated and degraded by 26 S proteasome, resulting in nuclear translocation of NF-κB (1–4).

The protein region responsible for the transcriptional activation (called the “transactivation domain” (TAD)) of p65 has been mapped in their unique C-terminal region containing at least two TADs within its C-terminal 120 amino acids, termed TA1 and TA2 (5–7). It has been revealed that the p65 TAD interacts with transcriptional coactivators, such as p300/CREB-binding protein (8, 9) and FUS/TLS (10), and general transcription factors, including TBP (11) and TFIIIB (7, 12). Interaction of p65 with these factors stimulates transcription by initiating chromatin remodeling or by recruiting RNA polymerase II. In an unexpected scenario, the involvement of ubiquitination has recently been implicated in the regulation of TADs of some transcriptional activators such as VP16 (13, 14), Myc (15), and nuclear receptors (16–18), either directly or indirectly (for an excellent review, see Conaway et al. (18)).

In this context, we became interested in AO7, which we have identified as one of the interacting proteins with the p65 TAD in the CytoTrap™ yeast two-hybrid screen. We have adopted this alternative screening method instead of the commonly used method utilizing the Gal4 transcription system, because the p65 TAD is functional in the yeast (10, 19). AO7 encodes a protein containing a RING finger domain and is ubiquitously expressed in various tissues (20). AO7 was initially identified in the yeast two-hybrid screen of a murine T cell library by using UbcH5b, an E2 enzyme, as bait (20). Although the target protein for the ubiquitination complex involving AO7 and UbcH5b still remains to be determined, AO7 has been shown to act as a putative E3 ligase at least in vitro (20). We found that AO7 acts as a mediator of p65 transcription. A possible mechanism of its action is discussed.

EXPERIMENTAL PROCEDURES

Plasmids—pSos-p65 (262–551), containing the C-terminal TAD of p65, a bait plasmid for the Cytotrap yeast two-hybrid screen, was generated by inserting the p65 C-terminal region corresponding to amino acids 262–551 into pSos (Stratagene), pCMV-p65, pGal4-p65, and its mutants, pGal4-p65(1–551), pGal4-p65N (containing amino acid positions 1–286 of p65), pGal4-p65C (containing amino acid positions 286–551 of p65), pGal4-p65C1 (containing amino acid positions 286–520 of p65), and pGal4-p65C3 (containing amino acid positions 521–551 of p65) were described previously (10, 19). pGal4-p65C2 containing amino acid positions 428–551 of p65, was constructed by PCR using 5’ and 3’ oligonucleotide primers containing an EcoRI site and HindIII site, respectively. pCMV-NIK (21) is a generous gift from D. Wallach (Weizmann Institute of Science, Rehovot, Israel). To generate pdDNA-AOT(1–459), pdDNA-AOT(1–219), and pdDNA-AOT(212–459), each containing a FLAG epitope tag in the N terminus, the various portions of AO7 cDNA were amplified by PCR using pGEMAO7, containing the full-length AO7 cDNA, as a template with 5’ and 3’ oligonucleotide primers containing an EcoRI site and HindIII site, respectively. These
products were digested with EcoRI and HindIII and subcloned in frame into pcDNA 3.1 vector (Invitrogen) at the EcoRI-HindIII site. Two RING-finger mutants, pcDNA-AO7(C159S) and pcDNA-AO7(C161S), were created using a commercial site-directed mutagenesis kit (QuikChange site-directed mutagenesis kit; Stratagene). pEGFP-AO7 was constructed by PCR using pGEMAO7 as a template with oligonucleotides containing SacI and HindIII sites and subcloned in frame into pGFP-N1 vector (Clontech). To generate pGEX-AO7(1–459), pGEX-AO7(1–219), pGEX-AO7(212–459), and pGEX-AO7(341–459), which express glutathione S-transferase (GST) fusion proteins, GST-AO7(1–459), GST-AO7(1–219), GST-AO7(212–459), and GST-AO7(341–459), respectively, the AO7 cDNA was amplified by PCR using pGEMAO7 as a template with 5′ and 3′ oligonucleotide primers containing EcoRI site and SfuI site, respectively. These products were digested with immobilized GST fusion proteins overnight at 4 °C in 1 ml of modified HEMNK buffer (40 mM HEPES-KOH (pH 7.5), 50 mM KCl, 1 mM MgCl₂, 0.2 mM EDTA, 0.1% Nonidet P-40, 1 mM diethio- ritol, 1× Complete™ protease inhibitors (Roche Applied Science)). After five washes with 1 ml of HEMNK buffer, bound radiolabeled proteins were eluted with 20 μl of Laemmli sample buffer, boiled for 3 min, and resolved by 10% SDS-PAGE.

**Yeast Two-hybrid Screening**—The CytoTrap™ (Stratagene) yeast screening was performed with human lung cDNA library (Stratagene) and pSso(262–511) as a bait according to the manufacturer’s instructions and the method previously described (24). Saccharomyces cerevisiae strain cdc25H was transformed sequentially with pSos-p65-(262–551) and pSos-(262–551) as a prey plasmid with human AO7 homologue, RNF25 (ring finger protein 25). The pSos-(262–551) was transfected, and cells were cultured for 48 h with or without 20 ng/ml of TNF stimulation for 30 min before the harvest. The cell extract was prepared by treatment with the lysis buffer (50 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5% Nonidet P-40, 10% glycerol, 1 mM diethiothreitol, and 1× Complete™ protease inhibitors) containing 120 μg/ml NaCl (low salt) or 300 μM (high salt). The cell lysate was incubated in the same buffer with 20 μl of anti-FLAG M2 Affinity Gel (Sigma) at 4 °C for 1 h with continuous rotation at 10 rpm. The beads were washed three times with 1 ml of lysis buffer. The antibody-bound complex was eluted by boiling in 1× Laemmli sample buffer. The immunoprecipitated proteins were resolved by 8% SDSPAGE and transferred on nitrocellulose membrane (Hybond-C; Amersham Biosciences). The membrane was incubated with rabbit polyclonal anti-p65 (C-terminal) antibody (Santa Cruz Biotechnology), and immunoreactive proteins were visualized by enhanced chemiluminescence (SuperSignal; Pierce) as described previously (28). To detect the tyrosine phosphorylation of p65 and FLAG-tagged AO7 expression, rabbit polyclonal anti-p65 antibody (Santa Cruz Biotechnology) and mouse monoclonal anti-FLAG (Sigma) were used.}

**RESULTS**

**Identification of AO7 as a Novel p65-interacting Protein by Yeast Two-hybrid Screen**—Although various p65-interacting proteins have been identified (6, 7, 10, 19), we have adopted CytoTrap™ (two-hybrid screening method) of the yeast to search for additional p65-interacting proteins. For this screening, the C-terminal region (residues 262–511) of NF-κB p65 subunit was fused to human Sos (hSos) and used as bait. The temperature-sensitive mutant S. cerevisiae strain cdc25H, containing a point mutation in the yeast homologue (cdc25) of the hSos gene, cannot grow at 37 °C but can grow at the permissive temperature (25 °C). This yeast strain was used to screen a human lung cDNA expression library fused to the v-Src myristylation sequence, thus anchoring the fusion protein to the plasma membrane. When the bait and target proteins physically interact, the hSos protein is recruited to the membrane, and the cdc25H yeast strain is enabled to grow at 37 °C.

We screened ~3.3 million transformants from the human lung cDNA library. Nucleotide sequence determination and comparison with GenBank™ databases (National Center for Biotechnology Information) revealed human IκBα (seven clones) and only one clone encoding human homologue of mouse AO7 (the corresponding protein of AO7 in human and mouse has also been termed RNF25; GenBank™ accession number NM022453). We isolated a full-length human AO7 cDNA clone from the library derived from human neuroblastoma cell line SK-N-MC (25) for further study.

To confirm the interaction between p65 and AO7 in vitro, we performed the GST pull-down assay. GST fusion proteins with various portions of AO7 (Fig. 1A) were synthesized in E. coli, immobilized on glutathione-Sepharose beads and incubated
Fig. 1. AO7 interacts with p65 in vitro and in vivo. A, schematic illustration of AO7 and its mutants. AO7 contains RWD domain and the RING finger motif and the Pro-rich region as predicted by SMART (38, 39) and Motif Scan (40), respectively. B and C, Binding between p65 and AO7 proteins were labeled with [35S]methionine in vitro. p65 and AO7 proteins were incubated with in vitro transcription/translation. B, radiolabeled p65 was incubated with GST, GST-AO7-(1–459), GST-AO7-(1–219), GST-AO7-(212–459), GST-AO7-(341–459), or GST-IκBα (positive control) immobilized on glutathione-Sepharose beads. The bound protein was eluted, resolved by 10% SDS-PAGE, and visualized by autoradiography. C, radiolabeled AO7s were incubated with GST and GST-p65-(441–521) and [35S]methionine-labeled AO7s (441–551) immobilized on glutathione-Sepharose beads. After incubation and further washing, the complexes were resolved by 10% SDS-PAGE and subjected to autoradiography.

Fig. 2. AO7 binds to p65 in vivo. 293 cells were transfected with pcDNA-AO7-(1–459) expressing the FLAG-tagged AO7. After 48 h of transfection, cells were stimulated with 20 ng/ml of TNF for 30 min in order to activate NF-κB. The AO7 was immunoprecipitated (IP) with anti-FLAG, the protein complex containing AO7 was resolved on 8% SDS-PAGE, and visualized by autoradiography. A, either low salt (120 mM NaCl) or high salt (300 mM NaCl) buffers were used for the immunoprecipitation to assess the binding affinity. The middle and lower panels show that equal amounts of p65 and AO7 were expressed in each transfection. WB, Western blot.
AO7 activates NF-κB through the transactivation domain of p65 (RelA)—To further investigate the effect of AO7 on NF-κB, various p65 mutants fused to Gal4BD (Fig. 5A) were cotransfected into 293 cells with the reporter plasmid, pFR1uc, in which luciferase gene expression is under the control of Gal4, with or without the AO7 expression plasmid pcDNA-AO7-(1–459). As shown in Fig. 5B, AO7 enhanced the Gal4-p65-dependent gene expression in a dose-dependent manner, and truncation of either the N-terminal (containing RING finger motif and RWD domain) or C-terminal (containing the Pro-rich region) half of AO7 abolished its action. These findings indicate that both the N- and C-terminal regions of AO7 are indispensable for its action. Moreover, these AO7 mutants did not block the transcriptional activity of p65, which is consistent with the results in Fig. 3B. There was no significant effect of AO7 on the VP16-mediated transactivation (data not shown).

We then explored the region of p65 responsible for the AO7-mediated transcriptional enhancement using various Gal4-p65 mutants. There was no significant effect of AO7 on Gal4-p65N, containing p65-(1–286) and lacking the TA domain (Fig. 5C). In contrast, AO7 stimulated the transcriptional activity of Gal4-p65C, containing nuclear localization signal, TA1, and TA2, in a dose-dependent manner (Fig. 5D). Further truncation and deletion of the C-terminal region of p65 revealed that both TA1 and TA2 are required for the action of AO7 (Fig. 5, E–G). Notably, since the extent of augmentation by AO7 for pGal4-p65C2 (8.3-fold) was greater than that for pGal4-p65C (12-fold) (Fig. 5, compare D and F), the central region, containing nuclear localization signal and thus serving as the target of IkB, is fully dispensable for the action of AO7, indicating that AO7 is unlikely to be involved in the IkB degradation. Moreover, since p65-(441–521) is shown to be sufficient for the interaction with AO7 (Fig. 1C), at least in vitro, the action of AO7 may require additional protein(s) interacting with TA1.
Effects of Mutation in the RING Finger Domain of AO7—AO7 contains a typical RING finger domain of the RING-H2 category, forming an interleaved zinc-binding site with six Cys residues and two His residues in the middle (C3H2C3) (Fig. 6A). These Cys and His residues of AO7 were shown to be crucial for its function such as ubiquitination and E2 binding (20). We thus introduced Cys substitutions and yielded two mutants: AO7(C159S), in which Cys at the irrelevant amino acid position 159 for RING was substituted by Ser, and AO7(C161S), in which Cys at 161, a crucial amino acid for the formation of RING and indispensable for ubiquitination and E2 binding, was substituted by Ser (20).

In Fig. 6B, the effects of these AO7 mutants were examined. Whereas the Cys mutation at 159, AO7(C159S), did not significantly affect the action of AO7, the Cys mutation at 161, substituting a crucial Cys for RING-H2 formation, exhibited no such action. At the higher amounts of AO7(C161S), the gene expression mediated by Gal4-p65 was inhibited in a dose-dependent manner, suggesting the dominant negative characteristics for this mutant. These findings indicated that the RING-H2 domain of AO7 is important for the action of AO7 and suggested that ubiquitination might be necessary for the augmentation of p65 transcriptional activity by AO7.

Selective Action of AO7 on p65—To further analyze the action of AO7, we examined whether AO7 could activate transcription when tethered to DNA. As shown in Fig. 7A, Gal4-AO7, containing the full-length AO7 fused to Gal4BD, did not activate transcription from a minimal promoter containing Gal4 binding sites, suggesting that AO7 does not act as a general coactivator of transcription. When pGal4-AO7 was cotransfected with pSport-p65, expressing full-length p65, the extent of gene induction was greatly augmented (up to 10-fold).
in a dose-dependent manner for the amount of pSport-p65 (Fig. 7B). When it was cotransfected with pVP16-p65, expressing a p65-VP16 fusion protein, a similar extent of gene induction (6-fold) was observed. However, when pVP16 was cotransfected with pGal4-AO7, no such effect was observed, presumably because of the lack of AO7 binding to VP16. Together with the results in Fig. 5, these observations indicate that AO7 interacts with p65 in cells and selectively supports the transactivation of p65.

DISCUSSION

Various factors modify the NF-κB transcriptional activity through interaction with p65 TAD. When NF-κB stimulates the transcription of target genes, transcriptional coactivators, such as p300/CREB-binding protein (8, 9) and FUS/TLS (10), and basal factors, including TBP (11) and TFII B (7, 12), interact with p65 TAD. It is likely that p65 TAD acts as an essential platform for the protein interaction. To further identify other protein(s) interacting with p65 TAD and elucidate the precise mechanism of gene activation, we adopted the CytoTrap™ yeast two-hybrid system because p65 TAD was fully functional in the conventional yeast two-hybrid assay utilizing the Gal4 transcription system (10, 19). Using the C-terminal region of p65 containing p65 TAD and nuclear localization signal as bait, we identified AO7 as an interacting partner as well as IκBα.

The interaction between p65 and AO7 was confirmed both in vitro and in vivo. Further mapping of the p65 interaction do-
main revealed that a portion of TAD (from aa 441 to 521 localized in TA2) is responsible for the interaction with AO7 in vitro. AO7 was localized predominantly in the nucleus and interacted with p65 in vivo upon stimulation with TNF. Interestingly, when AO7 was overexpressed, the transcriptional activity of p65 was greatly augmented, which was independent from the NF-κB activation cascade including TNF signaling and NIK. Using a heterologous transactivation system with the Gal4 DNA-binding domain fused with various portions of p65, we found that both TA1 and TA2 were required for the effect of AO7. Therefore, in addition to the AO7 binding to p65 TA2, other factors interacting with TA1, such as p300/CREB-binding protein coactivators (8, 9), may be involved in the AO7-mediated transcriptional activation.

AO7 was initially isolated as E2-interacting protein by conventional yeast two-hybrid screen and shown to bind UbcH5b through its RING finger motif (20). Although AO7 is known to accept the ubiquitin modification by E2 (UbcH5b), its biological function in vivo has not been elucidated. It was thus proposed that AO7 might act as an E3-like factor. However, its target proteins have not been found. In this study, we found that the RING finger motif of AO7 was not involved in the binding to p65 but required for the p65-mediated transactivation, suggesting a possibility that the AO7 might mediate the ubiquitination of p65 and enhance its transcriptional activity. However, we could not detect direct ubiquitination of p65 by AO7 or any change in the stability of p65 (data not shown). Therefore, the mechanism by which AO7 participates in the NF-κB-mediated transactivation is currently unknown.

Accumulating evidence that ubiquitin-modification plays a role in transcriptional regulation has been demonstrated (13–17). Ubiquitination appears to control transcription not only by mechanisms involving ubiquitin-dependent destruction of transcription factors or their inhibitors by proteasome but also by an intriguing mechanism independent of the proteasome (for a review, see Ref. 18). For example, most of the NF-κB activation pathways involve ubiquitination of its inhibitor IκBs followed by their degradation by proteasome and the generation of p50 and p52, DNA-binding subunits of NF-κB, from their precursors is mediated by ubiquitination-dependent proteinolysis (3, 4). It is possible that AO7 may facilitate protein processing of these proteins. Another possibility by which AO7 activates NF-κB is ubiquitination and degradation of corepressors such as Sin3A, N-CoR, or, more selectively, Groucho family proteins (19). In fact, Siah-2, a RING finger containing E3-like protein, is known to promote the ubiquitination of N-CoR and derepresses the gene expression (32).

There are many proteins that possess E3 ligase activity and inhibit the action of transcription factors. For example, the p53 inhibitor Mdm2, a RING finger-containing protein, inhibits the transcriptional activity of p53 by promoting ubiquitination and degradation of p53 (33). Another E3 protein, RING finger LIM domain-binding protein, inhibits the transcriptional activity of LIM homeodomain transcription factor family by interacting with the LIM cofactor and promoting its ubiquitination (34). Similarly, WWP1, a HECT family E3 ligase, binds to the lung Krüppel-like factor through its inhibitory domain and inhibits its transcriptional activity, although ubiquitination has not been demonstrated (35).

Interestingly, there are a number of reports suggesting a positive correlation between the ubiquitin-modification and the transcriptional activation. For example, although direct ubiquitination has not been demonstrated, Molinari et al. (36) demonstrated that half-lives of heterologous transactivators such as Gal4-VP16, Gal4-p65, Gal4-p53, and Gal4-CTF inversely correlated with the potency of their TADs. In addition, it was
demonstrated that the transactivation of VP16 TAD requires SCFMet30, a yeast E3, and fusion of a single ubiquitin moiety was sufficient to complement the deficiency of the SCFMet30 gene (14). These findings indicate that TAD-dependent ubiquitination may not only serve as a signal for its destruction but also be required for its function as an activator. Other examples include the involvement of E3 ligases, Rsp5/hPRF, E6-AP, and SNURF/RNF4, in the transactivation of various nuclear receptors (15–17). In addition, since a TAFII250 mutant lacking the ubiquitination catalytic activity failed to support the transactivation of Dorsal, a Drosohila homologue of RelA (37), the ubiquitination of histone H1 by TAFII250 is considered to be essential for the action of Dorsal.

Taken together, our findings raise a possibility that AO7 may support the transcriptional activity of NF-κB by several mechanisms. One such mechanism may be that the activated NF-κB interacts in the nucleus with various factors including general transcription factors, coactivators, and AO7. Formation of this complex may allow AO7 to direct ubiquitin modification of some of these factors, thus dissociating the transcriptional activator complex to initiate a subsequent step of transcription such as elongation. AO7 may also act as a scaffold protein for the interaction of transcription factors involved in the initiation complex. Further investigations are required to elucidate the mechanism by which AO7 supports the action of NF-κB and its biochemical actions.

Acknowledgments—We thank Drs. S. Sugano and D. Wallach for generosity in providing the full-length cDNA library and the expression vector encoding NIK, respectively.

REFERENCES
1. Baldwin, A. S., Jr. (1996) Annu. Rev. Immunol. 14, 649–683
2. Okamoto, T., Sakurada, S., Yang, J. P., and Merin, J. P. (1997) Curr. Top. Cell Regul. 35, 149–161
3. Karin, M., and Ben-Neriah, Y. (2000) Annu. Rev. Immunol. 18, 621–663
4. Ghosh, S., and Karin, M. (2002) Cell 109, suppl. 81–96
5. Moore, P. A., Ruben, S. M., and Rosen, C. A. (1993) Mol. Cell. Biol. 13, 1666–1674
6. Schmitz, M. L., dos Santos Silva, M. A., and Baeuerle, P. A. (1995) J. Biol. Chem. 270, 15576–15584
7. Schmitz, M. L., Steiger, G., Altmann, H., Meisterernst, M., and Baeuerle, P. A. (1995) J. Biol. Chem. 270, 7219–7226
8. Perkins, N. D., Felsen, L. K., Betts, J. C., Leung, K., Beach, D. H., and Nabel, G. J. (1997) Science 275, 523–527
9. Gerritsen, M. E., Williams, A. J., Neuh, A. S., Moore, S., Shi, Y., and Collins, T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2927–2932
10. Uraniushi, H., Tetsuka, T., Yamashita, M., Asamitsu, K., Shimizu, M., Itoh, M., and Okamoto, T. (2001) J. Biol. Chem. 276, 13395–13401
11. Xu, X., Prorock, C., Ishikawa, H., Maldonado, E., Ito, Y., and Gelinias, C. (1993) Mol. Cell. Biol. 13, 6733–6741
12. Kerr, L. D., Ransone, J. L., Wamsley, P., Schmitt, M. J., Boyer, T. G., Zhou, Q., Verma, I. M., and Herzenberg, L. A. (1997) Science 275, 412–415
13. Salghetti, S. E., Muratani, M., Wijnen, H., Futer, B., and Tansey, W. P. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 3118–3123
14. Salghetti, S. E., Caudy, A. A., Chenoweth, J. G., and Tansey, W. P. (2001) Science 293, 1651–1653
15. Moilanen, A. M., Poukka, H., Karvonen, U., Hakii, M., Janne, O. A., and Palvino, J. J. (1998) Mol. Cell. Biol. 18, 5128–5139
16. Nawar, Z., Lonard, D. M., Smith, C. L., Tsai, Y. S., Tsai, M. J., and O’Malley, B. W. (1999) Mol. Cell. Biol. 19, 1182–1189
17. Imhof, M. O., and McDonnell, D. P. (1996) Mol. Cell. Biol. 16, 2594–2605
18. Conaway, R. C., Brewer, C. S., and Conaway, J. W. (2002) Science 296, 1254–1258
19. Tetsuka, T., Uraniushi, H., Inai, H., Ono, T., Sonta, S., Takahashi, N., Asamitsu, K., and Okamoto, T. (2000) J. Biol. Chem. 275, 4383–4390
20. Larick, K. L., Jensen, J. P., Fang, S., Ono, A. M., Hatakeyama, S., and Weissman, A. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11364–11369
21. Malinin, N. L., Boldin, M. P., Kovalenko, A. V., and Wallach, D. (1997) Nature 383, 540–544
22. Yang, J. P., Hori, M., Takahashi, N., Kawabe, T., Katah, O., and Okamoto, T. (1999) Oncogene 18, 5177–5186
23. Sato, T., Asamitsu, K., Yang, J. P., Takahashi, N., Tetsuka, T., Yoneyama, A., Kanagawa, A., and Okamoto, T. (1998) AIDS Res. Hum. Retroviruses 14, 293–298
24. Yu, X., Li, P., Roeder, R. G., and Wang, Z. (2001) Mol. Cell. Biol. 21, 4614–4625
25. Suzuki, Y., Yoshimoto-Nakagawa, K., Maruyama, K., Saya, A., and Sugano, S. (1997) Gene (Amst.) 200, 149–156
26. Sakurada, S., Kato, T., and Okamoto, T. (1996) Int. Immunol. 8, 1483–1493
27. Takacs, N., Sandy, T., Okamoto, H., Yang, J. P., Asamitsu, K., Sarel, L., Kimura, G., Uraniushi, H., Tetsuka, T., and Okamoto, T. (2002) J. Virol. 76, 8019–8030
28. Kajino, S., Suganuma, M., Teranishi, F., Takahashi, N., Tetsuka, T., Ohara, H., Itoh, M., and Okamoto, T. (2000) J. Biol. Chem. 275, 32592–32597
29. Wang, D., and Baldwin, A. S., Jr. (1998) J. Biol. Chem. 273, 29411–29416
30. Sakurada, H., Chiba, H., Miyoshi, H., Sugita, T., and Toriumi, W. (1999) J. Biol. Chem. 274, 30353–30356
31. Wang, D., Westerheide, S. D., Hansen, J. L., and Baldwin, A. S., Jr. (2000) J. Biol. Chem. 275, 32592–32597
32. Zhang, J., Guenther, M. G., Carthew, R. W., and Lazar, M. A. (1998) Genes Dev. 12, 1773–1780
33. Fang, S., Jensen, J. P., Ludwig, R. L., Vosden, K. H., and Weissman, A. M. (2000) J. Biol. Chem. 275, 8945–8951
34. Gerondopoulos, H. P., Petrou, P. J., Peters, M. A., Schluter, A., Bossenz, M., Scheffner, M., and Bach, I. (2002) Nature 416, 99–103
35. Conkright, M. D., Wani, M. A., and Lingrel, J. B. (2001) J. Biol. Chem. 276, 29299–29306
36. Molinari, E., Gilman, M., and Natesan, S. (1999) EMBO J. 18, 6439–6447
37. Pham, A. D., and Sauer, F. (2000) Science 289, 2357–2360
38. Schultz, J., Milpetz, F., Bor, P., and Ponting, C. P. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5857–5864
39. Letunic, I., Goodstadt, L., Dickins, N. J., Doerks, T., Schultz, J., Mott, R., Ciccarelli, F., Copley, R. R., Ponting, C. P., and Bork, P. (2002) Nucleic Acids Res. 30, 242–244
40. Palequet, L., Pagni, M., Bucher, P., Hulo, N., Sigrist, C. J., Hofmann, K., and Bairoch, A. (2002) Nucleic Acids Res. 30, 235–238
RING Finger Protein AO7 Supports NF-κB-mediated Transcription by Interacting with the Transactivation Domain of the p65 Subunit

Kaori Asamitsu, Toshifumi Tetsuka, Satoshi Kanazawa and Takashi Okamoto

J. Biol. Chem. 2003, 278:26879-26887.
doi: 10.1074/jbc.M211831200 originally published online May 13, 2003

Access the most updated version of this article at doi: 10.1074/jbc.M211831200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

This article cites 40 references, 26 of which can be accessed free at http://www.jbc.org/content/278/29/26879.full.html#ref-list-1